BR112022023892A2 - Composições anti-vsig4 e métodos para modular fenótipos inflamatórios de células mieloides e seus usos - Google Patents

Composições anti-vsig4 e métodos para modular fenótipos inflamatórios de células mieloides e seus usos

Info

Publication number
BR112022023892A2
BR112022023892A2 BR112022023892A BR112022023892A BR112022023892A2 BR 112022023892 A2 BR112022023892 A2 BR 112022023892A2 BR 112022023892 A BR112022023892 A BR 112022023892A BR 112022023892 A BR112022023892 A BR 112022023892A BR 112022023892 A2 BR112022023892 A2 BR 112022023892A2
Authority
BR
Brazil
Prior art keywords
vsig4
compositions
methods
myeloid cell
cell phenotypes
Prior art date
Application number
BR112022023892A
Other languages
English (en)
Portuguese (pt)
Inventor
Culyba Elizabeth
Anh Nguyen Phuong
Razlog Maja
I Novobrantseva Tatiana
Feldman Igor
L Sazinsky Stephen
Original Assignee
Verseau Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verseau Therapeutics Inc filed Critical Verseau Therapeutics Inc
Publication of BR112022023892A2 publication Critical patent/BR112022023892A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112022023892A 2020-05-29 2021-05-28 Composições anti-vsig4 e métodos para modular fenótipos inflamatórios de células mieloides e seus usos BR112022023892A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063032337P 2020-05-29 2020-05-29
PCT/US2021/034784 WO2021243169A1 (en) 2020-05-29 2021-05-28 Anti-vsig4 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof

Publications (1)

Publication Number Publication Date
BR112022023892A2 true BR112022023892A2 (pt) 2022-12-27

Family

ID=78722851

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022023892A BR112022023892A2 (pt) 2020-05-29 2021-05-28 Composições anti-vsig4 e métodos para modular fenótipos inflamatórios de células mieloides e seus usos

Country Status (11)

Country Link
US (1) US20230348603A1 (enExample)
EP (1) EP4157886A4 (enExample)
JP (1) JP2023527410A (enExample)
KR (1) KR20230017778A (enExample)
CN (1) CN115996953A (enExample)
AU (1) AU2021281356A1 (enExample)
BR (1) BR112022023892A2 (enExample)
CA (1) CA3182814A1 (enExample)
IL (1) IL298545A (enExample)
TW (1) TW202210523A (enExample)
WO (1) WO2021243169A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023133338A2 (en) * 2022-01-10 2023-07-13 University Of Pittsburgh – Of The Commonwealth System Of Higher Education Molecules that bind to neutrophil elastase polypeptides
KR20240058017A (ko) * 2022-10-21 2024-05-03 주식회사 유틸렉스 항-vsig4 항체를 포함하는 항암용 조성물
CN116930505A (zh) * 2023-01-16 2023-10-24 中国人民解放军总医院第五医学中心 血细胞表达的vsig4膜蛋白作为生物标志物在急性单核细胞白血病和急性髓单核细胞白血病诊断中的应用
CN116380755B (zh) * 2023-03-20 2023-11-21 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） CD127+PMN-MDSCs在诊断支气管肺发育不良中的应用及诊断试剂盒
JP2025027841A (ja) * 2023-08-17 2025-02-28 国立大学法人 東京大学 ＶＳＩＧ４とＳｉｇｌｅｃ－７との分子間相互作用に対する抗ＶＳＩＧ４、抗Ｓｉｇｌｅｃ－７阻害抗体
KR20250062590A (ko) * 2023-10-31 2025-05-08 인제대학교 산학협력단 신장 이식 후 만성거부반응 진단용 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008130204A1 (en) * 2007-04-24 2008-10-30 Eucell Bio Co., Ltd. New anti-irc85 monoclonal antibody; and composition comprising the same for preventing and treating tuberculosis or enteritis disease; and the use thereof
WO2008151819A2 (en) * 2007-06-15 2008-12-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Treatment of tumors using specific anti-l1 antibody
EP2376120A2 (en) * 2008-11-25 2011-10-19 Biogen Idec MA Inc. Use of dr6 and p75 antagonists to promote survival of cells of the nervous system
JP5812418B2 (ja) * 2009-04-17 2015-11-11 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
KR101730868B1 (ko) * 2013-09-13 2017-04-27 인제대학교 산학협력단 Ｖｓｉｇ４ 억제제를 유효성분으로 포함하는 난소암 예방 또는 치료용 약학조성물
CN105924515B (zh) * 2016-04-25 2019-06-14 中国人民解放军第三军医大学 免疫共刺激分子vsig4激活性表位肽、单克隆抗体及其制备方法和应用
MA48763A (fr) * 2017-05-05 2020-04-08 Amgen Inc Composition pharmaceutique comprenant des constructions d'anticorps bispécifiques pour un stockage et une administration améliorés
EP3645042A4 (en) * 2017-06-26 2021-03-17 Bio-Techne Corporation HYBRIDOMA CLONES, MONOCLONAL ANTIBODIES DIRECTED AGAINST VSIG-4, AND THEIR MANUFACTURING AND USE METHODS
AU2019351294B2 (en) * 2018-09-28 2025-07-31 Eutilex Co., Ltd. Anti-human VSIG4 antibodies and uses thereof

Also Published As

Publication number Publication date
EP4157886A1 (en) 2023-04-05
WO2021243169A1 (en) 2021-12-02
US20230348603A1 (en) 2023-11-02
CA3182814A1 (en) 2021-12-02
IL298545A (en) 2023-01-01
KR20230017778A (ko) 2023-02-06
EP4157886A4 (en) 2024-10-16
CN115996953A (zh) 2023-04-21
JP2023527410A (ja) 2023-06-28
TW202210523A (zh) 2022-03-16
AU2021281356A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
BR112021024242A2 (pt) Composições e métodos anti-psgl-1 para modular fenótipos inflamatórios de células mieloides e usos dos mesmos
BR112021024314A2 (pt) Composições e métodos anti-siglec-9 para modular fenótipos inflamatórios de células mieloides e usos dos mesmos
BR112021026181A2 (pt) Composições anti-cd53 e métodos para modular fenótipos inflamatórios de células mieloides e usos dos mesmos
Zhai et al. Attenuation of rheumatoid arthritis through the inhibition of tumor necrosis factor–induced caspase 3/gasdermin E–mediated pyroptosis
Eppensteiner et al. Damage-and pathogen-associated molecular patterns play differential roles in late mortality after critical illness
Sava et al. Human pericytes adopt myofibroblast properties in the microenvironment of the IPF lung
Lin et al. Glycosylation‐dependent interaction between CD69 and S100A8/S100A9 complex is required for regulatory T‐cell differentiation
Nam et al. Changes of the structural and biomechanical properties of the bovine pericardium after the removal of α-gal epitopes by decellularization and α-galactosidase treatment
Netsch et al. Human mesenchymal stromal cells inhibit platelet activation and aggregation involving CD73-converted adenosine
Shi et al. Antimicrobial peptaibols, novel suppressors of tumor cells, targeted calcium-mediated apoptosis and autophagy in human hepatocellular carcinoma cells
Sharquie et al. An investigation into IgE-facilitated allergen recognition and presentation by human dendritic cells
Neri et al. Particulate matter induces prothrombotic microparticle shedding by human mononuclear and endothelial cells
Brandt et al. Galectin-1 induced activation of the apoptotic death-receptor pathway in human Jurkat T lymphocytes
Lee et al. Role of moesin in HMGB1-stimulated severe inflammatory responses
Chen et al. Protein disulfide isomerase enhances tissue factor-dependent thrombin generation
CR20230474A (es) Anticuerpos anti-cd19 y estructuras car-t
Yeung et al. Extracellular histones induced eryptotic death in human erythrocytes
BR112021026411A2 (pt) Composições anti-lrrc25 e métodos para modular fenótipos inflamatórios de células mieloides e usos dos mesmos
BR112023005980A2 (pt) Anticorpos cd1a e seus usos
PH12021551994A1 (en) Anti-cd6 antibody compositions and methods for treating lupus
Drake et al. Targeting the endoplasmic reticulum mediates radiation sensitivity in colorectal cancer
Taniuchi et al. BART inhibits pancreatic cancer cell invasion by Rac1 inactivation through direct binding to active Rac1
Shojaee et al. Myosin translocation in retinal pericytes during free‐radical induced apoptosis
Sahadevan et al. Unique, polyfucosylated glycan–receptor interactions are essential for regeneration of Hydra magnipapillata
Cherian et al. Recombinant mucin-type fusion proteins with a Galα1, 3Gal substitution as Clostridium difficile toxin A inhibitors

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]